Literature DB >> 26087338

General population screening for type 1 diabetes: has its time come?

Richard A Insel1, Jessica L Dunne, Anette-G Ziegler.   

Abstract

PURPOSE OF REVIEW: The purpose of this review was to describe the potential for general childhood population-based screening of risk of symptomatic type 1 diabetes (T1D) RECENT
FINDINGS: The earliest stages of T1D can be identified and risk and rate of progression to symptomatic disease can be estimated by the presence of multiple islet autoantibodies and glucose intolerance (dysglycemia) in individuals screened for risk. Screening for human leukocyte antigen risk genotypes in neonates with follow-up detection of islet autoantibodies in childhood has been explored. An alternative approach of general childhood population-based detection of autoantibodies at well child visits provides an approach to detect a high proportion of children who will develop T1D. The Fr1da study was launched in Bavaria in 2015 to explore this concept.
SUMMARY: General childhood population-based screening for risk of T1D will allow detection of an at-risk population that can participate in natural history studies to better understand disease pathogenesis and intervention trials to prevent symptomatic disease and will provide a framework for public health-based prevention of childhood-onset T1D.

Entities:  

Mesh:

Year:  2015        PMID: 26087338     DOI: 10.1097/MED.0000000000000173

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  17 in total

1.  Alternate Ways to Quantify Antibodies.

Authors:  Kimber M Simmons; Aaron W Michels
Journal:  Diabetes Technol Ther       Date:  2015-11-06       Impact factor: 6.118

2.  A peripheral blood transcriptomic signature predicts autoantibody development in infants at risk of type 1 diabetes.

Authors:  Ahmed M Mehdi; Emma E Hamilton-Williams; Alexandre Cristino; Anette Ziegler; Ezio Bonifacio; Kim-Anh Le Cao; Mark Harris; Ranjeny Thomas
Journal:  JCI Insight       Date:  2018-03-08

Review 3.  Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?

Authors:  Manuela Battaglia; Laura Nigi; Francesco Dotta
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

Review 4.  Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.

Authors:  Carla Greenbaum; Sandra Lord; Dana VanBuecken
Journal:  Curr Diab Rep       Date:  2017-10-17       Impact factor: 4.810

5.  Prediction of type 1 diabetes using a genetic risk model in the Diabetes Autoimmunity Study in the Young.

Authors:  Brigitte I Frohnert; Michael Laimighofer; Jan Krumsiek; Fabian J Theis; Christiane Winkler; Jill M Norris; Anette-Gabriele Ziegler; Marian J Rewers; Andrea K Steck
Journal:  Pediatr Diabetes       Date:  2017-07-11       Impact factor: 4.866

6.  High-Throughput Multiplex Electrochemiluminescence Assay Applicable to General Population Screening for Type 1 Diabetes and Celiac Disease.

Authors:  Ling He; Xiaofan Jia; Cristy Geno Rasmussen; Kathleen Waugh; Dongmei Miao; Fran Dong; Brigitte Frohnert; Andrea K Steck; Kimber M Simmons; Marian Rewers; Liping Yu
Journal:  Diabetes Technol Ther       Date:  2022-05-25       Impact factor: 7.337

7.  Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Authors:  Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2018-04       Impact factor: 19.112

8.  Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression.

Authors:  Chih-Wei Liu; Lisa Bramer; Bobbie-Jo Webb-Robertson; Kathleen Waugh; Marian J Rewers; Qibin Zhang
Journal:  J Proteomics       Date:  2017-10-07       Impact factor: 4.044

9.  Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.

Authors:  Anette-Gabriele Ziegler; Kerstin Kick; Ezio Bonifacio; Florian Haupt; Markus Hippich; Desiree Dunstheimer; Martin Lang; Otto Laub; Katharina Warncke; Karin Lange; Robin Assfalg; Manja Jolink; Christiane Winkler; Peter Achenbach
Journal:  JAMA       Date:  2020-01-28       Impact factor: 56.272

Review 10.  Diabetes type 1: Can it be treated as an autoimmune disorder?

Authors:  Natalia G Vallianou; Theodora Stratigou; Eleni Geladari; Christopher M Tessier; Christos S Mantzoros; Maria Dalamaga
Journal:  Rev Endocr Metab Disord       Date:  2021-03-17       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.